CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration by Fox, James M et al.
1Scientific RepoRts |  (2018) 8:9466  | DOI:10.1038/s41598-018-27710-9
www.nature.com/scientificreports
CXCL4/Platelet Factor 4 is an 
agonist of CCR1 and drives human 
monocyte migration
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Activated platelets release micromolar concentrations of the chemokine CXCL4/Platelet Factor-4. 
Deposition of CXCL4 onto the vascular endothelium is involved in atherosclerosis, facilitating monocyte 
arrest and recruitment by an as yet, unidentified receptor. Here, we demonstrate that CXCL4 drives 
chemotaxis of the monocytic cell line THP-1. Migration and intracellular calcium responses induced 
by CXCL4 were pertussis toxin-sensitive, implicating a GPCR in signal transduction. Cell treatment 
with chondroitinase ABC ablated migration, suggesting that cis presentation of CXCL4 by cell surface 
glycosaminoglycans to a GPCR is required. Although CXCR3 has been previously described as a CXCL4 
receptor, THP-1 cells were unresponsive to CXCR3 ligands and CXCL4-induced migration was insensitive 
to a CXCR3 antagonist, suggesting that an alternative receptor is involved. Interrogating CC-class 
chemokine receptor transfectants, we unexpectedly found that CXCL4 could induce the migration of 
CCR1-expressing cells and also induce CCR1 endocytosis. Extending our findings to primary human 
monocytes, we observed that CXCL4 induced CCR1 endocytosis and could induce monocyte chemotaxis 
in a CCR1 antagonist-sensitive manner. Collectively, our data identify CCR1 as a previously elusive 
monocyte CXCL4 receptor and suggest that CCR1 may play a role in inflammation where the release of 
CXCL4 is implicated.
Chemokines represent a large family of small peptides that typically signal via G protein-coupled receptors 
(GPCRs) and which recruit leukocytes to inflammatory sites and lymphoid microenvironments1. Chemokines 
are classified as belonging to one of four distinct groups based on the conservation of amino-terminal cysteine 
residues2. The chemokines belonging to two main classes contain a pair of cysteine residues, which are either 
adjacent (CC class) or separated by a single amino acid (CXC class). Signaling is considered to be class-restricted, 
with CC-chemokines activating CC receptors and CXC chemokines activating CXC receptors. Both CC and 
CXC chemokines have been shown to be highly expressed in the atherosclerotic plaques of humans and rodents, 
implying that enhanced leukocyte recruitment to the plaque is a driver of disease3. Supportive of this, deletion of 
several key chemokine receptors has been shown to protect against the development of atherosclerosis in murine 
models4–6, suggesting that targeting chemokine receptors may be therapeutically beneficial7.
CXCL4/Platelet Factor-4 was the first member of the chemokine family to be discovered8 and is found at 
significant levels in atherosclerotic plaques, where its abundance correlates with lesion severity9. Several lines of 
evidence suggest that CXCL4 is an important player in atherogenesis. CXCL4 is released in micromolar concen-
trations following platelet activation and its deposition on the endothelium has been shown to exacerbate ather-
osclerotic lesion formation in Apolipoprotein E-deficient mice10. Consistent with this role, deletion of CXCL4 on 
the same genetic background results in reduced atherosclerotic lesion size11. CXCL4 exerts numerous effects on 
monocytes, although its roles appear to be complex. There is some debate as to whether or not CXCL4 alone is 
able to induce monocyte migration12,13, although CXCL4 has been shown to form functional heterodimers with 
CC chemokines such as CCL5/RANTES that promote monocyte arrest on endothelium14. These CXCL4/CCL5 
heterodimers are atherogenic, since inhibition of their formation by small molecule antagonists is protective in a 
mouse model of atherosclerosis15.
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Although the chemokine receptors CXCR3-A and CXCR3-B have been shown to mediate endothelial and 
T-cell signaling in response to CXCL416–18, the receptor by which CXCL4 signals in human monocytes has proved 
elusive. This has hampered efforts to further elucidate the biology of this chemokine. In this study we provide 
several clear lines of evidence to demonstrate that CXCL4 is an agonist of the CC chemokine receptor CCR1 and 
that this receptor mediates CXCL4-signaling in human monocytes. This has implications for its targeting in the 
treatment of atherosclerosis and other inflammatory diseases.
Results
Functional responses induced by CXCL4 treatment of monocytic THP-1 cells. The monocytic 
line THP-1 was initially examined by chemotaxis assays using a modified Boyden chamber. Cells were highly 
responsive to CCL7, as we have previously described19, with a 10 nM concentration of CCL7 inducing a robust 
response (Fig. 1A). Migration to CXCL4 was less potent, with migration only observed at a concentration of 1 μM 
CXCL4. No migration of THP-1 cells to the CXCR3 ligands CXCL10 and CXCL11 was observed (Fig. 1A), nor 
could we detect significant levels of cell surface CXCR3 expression with a specific antibody nor specific binding 
of radiolabeled CXCL10 (Supplementary Fig. 1). This suggests that in contrast to CXCL4 signaling in T cells17,18, 
CXCL4 responses in THP-1 cells are not mediated by either of the CXCR3 variants. This was supported by the 
lack of effect of a CXCR3 antagonist on CXCL4 induced responses (Supplementary Figure 1) and is in agreement 
with other studies citing either a lack of CXCR3-B mRNA in monocytes20 or no effect of a CXCR3 antagonist on 
CXCL4-induced monocyte responses21. Using an extended concentration range of CXCL4, a bell-shaped migra-
tory curve typical of other chemokines was observed (Fig. 1B). In keeping with the findings of several groups 
Figure 1. THP-1 cells respond to CXCL4 - Panels A and B. Migratory responses of THP-1 cells to increasing 
concentrations of CXCL4, CCL7, CXCL10 and CXCL11 (n = 4, Panel A; n = 3 Panel B). Panel C. Migratory 
responses of THP-1 cells to 1 μM CXCL4 or 10 nM CCL7 in the presence or absence of a concentration gradient 
(n = 4). Panels D-G. Intracellular calcium flux of THP-1 cells in response to CXCL4 and CCL7, following 
culture in the absence (Panels D, E) and presence (Panels F, G) of pertussis toxin (PTX). Arrowheads indicate 
point of chemokine addition (representative of n = 3).
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studying CXCL4 signaling in a variety of cell types12,22–24, micromolar concentrations of CXCL4 were required 
to induce migration, suggesting that the affinity of CXCL4 for its receptor is likely to be low. To assess the relative 
contributions of chemokinesis and chemotaxis to THP-1 cell migration, optimal concentrations of CCL7 and 
CXCL4 were placed either in the bottom compartment of a modified Boyden chamber or in both the top and 
bottom compartments (Fig. 1C). Whilst the inclusion of CCL7 in the upper compartment significantly reduced 
THP-1 migration (indicative of a largely chemotactic component), the inclusion of CXCL4 in the upper compart-
ment had no significant effect upon CXCL4-induced migration. This suggests that a gradient of CXCL4 is not 
required to induce migration of THP-1 cells when assayed with a modified Boyden chamber.
CXCL4 treatment of THP-1 cells was also observed to give rise to an increase in intracellular calcium (Fig. 1D), 
as was treatment with the chemokine CCL7 (Fig. 1E). Pre-treatment of THP-1 cells with pertussis toxin ablated 
both the induction of intracellular calcium release (Fig. 1F and G) and THP-1 cell migration (Supplementary 
Fig. 1) in response to either CXCL4 or CCL7, suggesting that these signals are mediated via GPCRs that couple 
to Gαi proteins. Petersen and colleagues have previously reported that CXCL4 binds to one or more chondroitin 
sulphate-decorated glycoproteins on the surface of neutrophils, which is necessary for the biological activity 
of CXCL4, since enzymatic removal of cell surface chondroitin ablates functional responses25,26. Similarly, we 
observed that pre-treatment of THP-1 cells with the enzyme chondroitinase ABC significantly reduced the migra-
tion of THP-1 cells to not only CXCL4 but also to CCL7, whilst heparinase treatment had no effect (Fig. 2A and B). 
These data suggest that one or more chondroitin sulphate-decorated glycoproteins present CXCL4 in cis to a 
specific GPCR.
To supplement our Boyden chamber chemotaxis data, we switched to a novel horizontal device for imaging 
leukocyte migration in real time, namely the TAXIScan27. In this device, cells are introduced at one end of a 5 μm 
deep microchannel and chemoattractant is introduced at the other. Migration of cells to chemoattractant within 
the channel is then monitored via a charge coupled device camera, with the data subjected to manual cell track-
ing (Supplementary Fig. 2). THP-1 cells were introduced into the chambers and their migration in response to 
CCL2, to CXCL4 or in the absence of stimulation was recorded over a 2 hr period (Fig. 3). Migration to CCL2 was 
typically robust, with many cells migrating towards the source of chemokine (Fig. 3A, Supplementary Video 1). 
Likewise, several cells were seen to migrate along a gradient of CXCL4 (Fig. 3B, Supplementary Video 2). In both 
cases, cells were seen to generate relatively long protrusions in the direction of the gradient prior to migration 
Figure 2. Chondroitin sulphates are required for chemotaxis - Chemotaxis of THP-1 cells in response to 
CXCL4 (Panel A) and CCL7 (Panel B), following incubation of cells in the presence and absence of heparinase 
and chondroitinase (n = 3).
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in the same direction. In contrast, relatively few cells migrated along the microchannel in the absence of stim-
ulation (Fig. 3C, Supplementary Video 3). The tracks of individual cells were subjected to further analysis. The 
mean track length of cells responding to CXCL4 or CCL2 was seen to be significantly greater than that of cells 
not subjected to a stimulus (Fig. 4A). Velocity Directionality Box (VD-Box) plots of migration were subsequently 
generated, in which each symbol corresponds to an individual cell (Fig. 4B). In a visual system, better designed 
to assess cellular migration and differentiate between chemotaxis and chemokinesis, cells exposed to gradients of 
either CXCL4 or CCL2 had a significantly higher directionality value compared to unstimulated cells (plotted to 
the right most area of the graph) indicating that both CXCL4 and CCL2 induce the directional migration (chem-
otaxis) of THP-1 cells. The velocity of cells migrating in response to CXCL4 or CCL2 trended towards an increase 
over basal cell velocity but this was not significant.
Figure 3. CXCL4 drives the chemotaxis of THP-1 cells as visualized via TAXIScan - Panels A-C show 
chemotaxis of THP-1 cells along a gradient of CCL2 (A), CXCL4 (B) as illustrated or in the absence of 
stimulation (C) as assessed for 2 hr at 37 °C. Data shown are pooled from replicate conditions from 3 individual 
experiments.
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CXCL4 is an agonist of CCR1. We have previously shown that responses to CCL7 in THP-1 cells are medi-
ated predominantly via CCR119. We observed that the most robust responses in the Boyden chamber assay to 
CXCL4 were obtained with THP-1 cells that were also the most responsive to CCL7. We therefore postulated that 
contrary to the current dogma that chemokine receptor activation is class-restricted (i.e. CXC chemokines acti-
vate only CXC receptors), CXCL4 might be acting by a known CCL7 receptor. To test this hypothesis, we trans-
fected the mouse pre-B cell line L1.2 with plasmids encoding the three CC chemokine receptors at which CCL7 is 
known to be an agonist, namely CCR1, CCR2 and CCR3. All three receptors were readily expressed in a transient 
manner (Fig. 5A,B,C) and cells correspondingly responded to their cognate ligands CCL3, CCL2 and CCL11 in 
Boyden chamber assays (Fig. 5D,E,F). Notably, a significant response over basal migration to micromolar con-
centrations of CXCL4 was singularly observed in CCR1 transfectants (Fig. 5D), albeit a less potent and efficacious 
response than that observed with CCL3, suggesting that CXCL4 is a partial agonist of CCR1 in this assay.
We next sought to validate whether a well-characterized small molecule antagonist of CCR1 named UCB 
3562528,29 was able to block CXCL4 signaling. Using L1.2 cells stably expressing high levels of CCR1, we again 
observed robust migration responses in Boyden chamber assays to both CCL3 and CXCL4 (Fig. 6A). As we had 
observed with THP-1 cells, migration to CXCL4 in the Boyden chamber assay was unaffected by the inclusion of 
CXCL4 both above and below the filter (Fig. 6B). This was in contrast to CCL3 responses which were significantly 
inhibited by including CCL3 both above and below the filter. As was the case with THP-1 cells, (Fig. 2) preincuba-
tion of L1.2 cells expressing CCR1 with chondroitinase was found to significantly inhibit the migration to CXCL4 
whilst responses to CCL3 remained intact (Fig. 6C). Preincubation of cells with a 10 μM concentration of UCB 
35625 was able to ablate migration to optimal concentrations of both CCL3 and CXCL4 but had no significant 
effect upon migration to the CXCR4 ligand CXCL12 (Fig. 6D). Unlike naïve L1.2 cells29, the L1.2 CCR1 transfect-
ants displayed a detectable level of migration in the absence of chemokine but this was significantly increased by 
exposure to 1 μM CXCL4 (p = 0.0025). Basal migration was significantly inhibited by preincubation with UCB 
35625, suggesting that when expressed at high levels, CCR1 shows a degree of constitutive activity, which is able 
to drive migration, as previously reported by Gilliland and colleagues30. Ligand binding assays were also under-
taken in which CXCL4 was observed to be unable to compete with radiolabelled CCL3 for binding to CCR1, 
unlike unlabeled CCL3 which was able to displace radiolabelled CCL3 with ease (Fig. 6E).
Figure 4. Analysis of THP-1 cell chemotaxis via TAXIScan - Panel A shows the mean track length observed 
for THP-1 cells exposed to the various stimuli using the data shown in Fig. 3. Panel B shows a Velocity-
Directionality Box (VD-B) plot of the same data. Each symbol corresponds to an individual cell exposed to 
stimuli as indicated by the key. Median values of directionality and velocity (with the range) are are shown 
alongside as a box plot.
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In addition to initiating receptor signaling, chemokines also classically induce receptor endocytosis follow-
ing binding. We therefore assessed the ability of 50 nM CCL3 or 1 μM CXCL4 to induce receptor endocytosis 
in THP-1 cells, the L1.2-CCR1 line and freshly isolated human monocytes (Fig. 7). Incubation of THP-1 cells 
with CCL3 at 37 °C induced a significant loss of cell surface CCR1 whilst CXCL4 was without significant effect 
(Fig. 7A). In contrast, when L1.2 CCR1 transfectants were examined, incubation with either CCL3 or CXCL4 
was able to induce significant CCR1 endocytosis (Fig. 7B). Similarly, when human monocytes were examined, 
both CCL3 and CXCL4 induced significant CCR1 endocytosis at levels similar to those induced in the L1.2 CCR1 
cell line. Collectively, these data confirm our findings that CXCL4 is a CCR1 agonist, although the cellular back-
ground in which CCR1 is expressed appears to dictate the efficacy of CXCL4-induced endocytosis.
Blockade of CCR1 ablates monocyte migration in response to CXCL4. Having implicated CCR1 
in CXCL4 signaling using a transfectant system and a monocytic cell line we sought to translate our migratory 
findings to assays using freshly isolated human monocytes. The TAXIScan device27 was employed to examine 
realtime migration of monocytes. This system also circumvents the problems of monocytes adhering to the filters 
of modified Boyden chambers, which can make analysis problematic. Exposure of monocytes to a gradient of 
CCL2 and CXCL4 resulted in robust migration, whilst considerably fewer monocytes were observed to migrate 
in the absence of chemokine (Fig. 8A,B,C, Supplementary Videos 4, 5 and 6). Unlike the THP-1 cells, no long 
protrusions were observed to be generated prior to migration. Tracking of individual monocytes revealed that 
Figure 5. CCR1 mediates CXCL4-induced leukocyte migration in a transfectant system- Panels A, B, C show 
transient expression of HA-tagged variants of the known signaling CCL7 receptors, CCR1, CCR2 and CCR3 as 
assessed by flow cytometry using an HA-specific mAb (open histogram) or isotype control (filled histogram). 
Panels D, E, F show the migratory responses of the same transfectants to CXCL4 and to control chemokines 
(n = 3).
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the mean track length of monocytes migrating along a gradient of CCL2 was significantly shorter than those 
of monocytes exposed to a gradient of CXCL4 or not exposed to a stimulus (Fig. 9A). This finding was further 
clarified when the directionality and velocity parameters were assessed in a VD-B plot (Fig. 9B). Cells migrating 
in response to both CCL2 and CXCL4 had significantly greater directionality than those undergoing basal migra-
tion. In contrast, when the velocity of migration was examined, CCL2 stimulation resulted in significantly slower 
migration than observed in either basal migration or migration in response to CXCL4 stimulation. Collectively, 
these data show that that both CCL2 and CXCL4 induce the chemotaxis of monocytes, with CCL2 inducing a 
slower, more methodical migration.
To confirm that the CXCL4-induced migration was mediated via CCR1, we assessed whether it was sensitive 
to pre-treatment with the CCR1 antagonists UCB 35625 and BX-471. The accumulated distance migrated by 
monocytes (i.e. the sum of the individual cell tracks) either along a CXCL4 gradient, along a CCL2 gradient or 
in the absence of stimulation was examined using monocytes pretreated with vehicle or with 10 μM UCB 35625 
Figure 6. CXCL4 is an agonist of CCR1 - Panel A shows chemotactic responses to CCL3 and CXCL4 of an L1.2 
transfectant line stably expressing CCR1 (L1.2-CCR1), (n = 6). Panel B shows migration of L1.2-CCR1 cells in a 
modified Boyden chamber to 1 μM CXCL4 or 10 nM CCL3 in the presence or absence of a chemokine gradient 
(n = 4). Panel C shows migration of the L1.2-CCR1 cell line to the same stimuli following incubation of cells in 
the presence and absence of heparinase and chondroitinase (n = 4). Panel D shows the blockade of no stimulus, 
CCL3 and CXCL4 migratory responses in the same stable cell line by the CCR1-specific antagonist UCB 35625 
(n = 7); responses to CXCL12 were unaffected (n = 4). Panel E shows competitive binding assays where 125I-
CCL3 was displaced from L1.2-CCR1 cells with increasing concentrations of unlabeled CCL3 but not with 
CXCL4 (n = 4). Statistical values indicated refer to paired t-tests.
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or BX-471. Migration in response to CXCL4 was significantly inhibited by pretreated of cells with 10 μM UCB 
35625 when compared to vehicle treated cells (Fig. 10A) whilst basal migration, or migration along a gradient 
of CCL2 was unaffected (Fig. 10B). This is in line with our previous findings regarding the lack of activity of this 
compound in blocking CCL2 responses in monocytes28. Similarly, pretreatment of cells with 10 μM BX-471, an 
alternative CCR1 antagonist, was seen to significantly inhibit the migratory responses to CXCL4 but not the basal 
migration (Fig. 10C).
Figure 7. Induction of CCR1 endocytosis by CXCL4. - Panels A, B and C show CCR1 endocytosis in THP-1 
cells (A) L1.2-CCR1 cell line (B) and freshly isolated human monocytes (C) following incubation with CCL3 
or CXCL4 at 37 °C or 4 °C Data are from 4, 5 and 5 experiments respectively. Statistical values indicated refer to 
paired t-tests.
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Discussion
The release of micromolar concentrations of CXCL4 by activated platelets has been implicated in the process 
of atherogenesis by virtue of its many effects upon monocytes, notably their endothelial arrest, recruitment to 
the sub-endothelial space and effects on survival and differentiation10,14,20,23,31. We present here a body of data 
that clearly identifies CXCL4 as a CCR1 agonist. Notably, we observed that CCR1 could induce the migration of 
CCR1-transfctants, albeit with reduced potency and efficacy when compared to the principal CCR1 ligand, CCL3. 
Figure 8. CXCL4 drives the chemotaxis of human monocytes. Panels A–C show migration of monocytes along 
gradients of CCL2 (A) or CXCL4 (B) compared to no stimulus (C) as assessed by TAXIScan for 2 hr at 37 °C. 
Data shown are pooled from replicate conditions (n = 6). The total number of cells migrated is shown in the 
upper right hand corner.
www.nature.com/scientificreports/
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This is reminiscent of our earlier findings with CXCR3, where CXCL4 was observed to have reduced potency and 
efficacy when compared with the other CXCR3 ligands17. Since the current dogma suggests that chemokines are 
class restricted, i.e. CXC chemokines activate only CXC chemokine receptors, the finding that CXCL4 activates 
CCR1 was unexpected and serves to underline the apparent plasticity of some chemokine receptors with respect 
to ligand recognition. For example, β-defensin induces T-cell migration via CCR632, whilst ubiquitin has been 
shown to be a ligand for CXCR433. Similarly, the atypical chemokine receptor ACKR1, previously known as Duffy 
Antigen Receptor for Chemokines (DARC) is well known to bind chemokines of both CC and CXC classes34.
In keeping with the findings of many other groups studying aspects of CXCL4 signalling in a variety of cell 
types12,17,18,22–24, micromolar concentrations of CXCL4 were required to observe biological effects, suggesting 
that the affinity of CXCL4 for its receptor is likely to be low. Petersen and colleagues previously reported that 
CXCL4 bound to the surface of neutrophils with a Kd of less than 600 nM which they attributed to the binding of 
tetrameric CXCL4 to a chondroitin sulphate-containing cell surface glycoprotein of around 250 kDa, considera-
bly larger than most GPCRs25,26. Similarly, von Hundelshausen and colleagues have shown that CXCL4-induced 
monocyte arrest on ECs requires chondroitin sulphate14. We observed that pre-treatment with the enzyme chon-
droitinase ABC markedly reduced the migration of THP-1 cells and CCR1 transfectants to CXCL4 which sug-
gests that one or more glycoproteins decorated with chondroitin sulphate provide cis presentation of CXCL4 
to CCR1 on the monocyte surface, which is critical for receptor activation (Fig. 11). A similar mechanism by 
which glycosaminoglycans on the surface of T-cells present CCL5 to the receptor CCR5 has previously been put 
forward35, with treatment with a cocktail of glycanases resulting in a loss of T-cell responses to CCL5. Consistent 
with this, we were unable to effectively compete CCL3 from the surface of CCR1 transfectants with CXCL4. This 
is reminiscent of our earlier study examining CXCL4 activation of CXCR3, where we were unable to demonstrate 
displacement of CXCL11 from CXCR3 by CXCL4, despite clearly showing CXCR3-mediated CXCL4 signalling, 
with glycosamingoglycans necessary for CXCL4 function17.
In addition to activity on CCR1 transfectants, we observed that CXCL4 could induce the migration of the 
monocytic cell line THP-1 in a modified Boyden chamber. These data were ably supported by realtime imag-
ing of cell migration using a TAXIScan system in which CXCL4 clearly induced the directed migration of both 
THP-1 cells and monocytes. Although an earlier report suggested that CXCL4 was chemotactic for neutrophils 
and monocytes13, this was subsequently contested by Petersen and colleagues who failed to observe monocyte 
Figure 9. Analysis of monocyte chemotaxis via TAXIScan - Panel A shows the mean track length traveled by 
cells in response to each stimulus using the data shown in Fig. 8. Panel B shows a Velocity-Directionality Box 
(VD-B) plot of the same data. Each symbol corresponds to an individual cell exposed to stimuli as indicated by 
the key. Median values of directionality and velocity (with the range) are shown alongside as a box plot.
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migration in response to a highly purified preparation of CXCL4 in Boyden chamber assays12. Their argument 
was that the original migration observed by Deuel and colleagues13 was likely due to contamination with other 
chemokines in the platelet-derived CXCL4 preparation. Here, we have used a highly pure recombinant form 
of CXCL4 (greater than 98 percent purity as determined by Western blotting and HPLC analysis) so can con-
fidently attribute the observed chemotactic activity to CXCL4 alone. In keeping with our CCR1 transfectant 
data, CXCL4-induced migration of THP-1 cells and monocytes was CCR1-dependent, as shown by the action 
of the small molecule antagonists UCB 35625 and BX-471. It is unclear why in the Boyden chamber assays, the 
inclusion of chemokine above the membrane had no effect on CXCL4 responses, suggesting at face value, that the 
CXCL4-induced migration was chemokinetic (non-directional). This is clearly not the case, as the TAXIScan data 
(movies and VD-B plots) shows the migration to be chemotactic. The flaws of assessing chemokinesis in Boyden 
chambers are well known, hence the initial development of Dunn and Zigmond chambers and systems such as 
TAXIScan. It is debatable in modified Boyden chamber assays whether or not a chemoattractant gradient exists 
for the duration of the assay and the validity of the “checkerboard” correction for chemokinesis measurements 
has been questioned36. Our data highlights the need for direct visualisation to accurately examine the migratory 
behavior of cells in a chemotactic gradient, as suggested by others37.
In addition to its ability to induce monocyte arrest and migration, CXCL4 can also act as a differentiation and 
survival factor for monocytes, generating what has been dubbed the “M4” macrophage23. The transcriptional 
program induced by CXCL4 appears to be distinct from those induced by classical and non-classical activa-
tion, including apparently contradictory pro-atherosclerotic and anti-atherosclerotic components, such as down 
Figure 10. CXCL4-induced monocyte migration is sensitive to CCR1 antagonism- Panels A and B show the 
accumulated migration of monocytes in response to no stimulus, CXCL4 (Panel A, n = 6) or CCL2 (Panel 
B, n = 3) following pre-incubation with vehicle or the CCR1-antagonist UCB 35625. Panel C shows the 
accumulated migration of monocytes in response to no stimulus or CXCL4 following pre-incubation with 
vehicle or the CCR1-antagonist BX-471 (n = 4).
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regulation of the atheroprotective scavenger CD163 and down regulation of the atherogenic scavenger CD3620. 
Notably, the M4 macrophage takes up much less modified low density lipoprotein (LDL) than those differenti-
ated by M-CSF treatment23. If we extrapolate our findings here that CCR1 is a bona fide receptor for CXCL4 on 
monocytes, then our findings may explain at a mechanistic level why deletion of CCR1 in mice has been shown 
to enhance atherosclerosis in two independent studies38,39. This is in stark contrast to several other studies of 
chemokine receptor-deficient mice that display various levels of atheroprotection4,5. In light of our data here, we 
speculate that the accelerated atherosclerosis seen in the CCR1 deficient mice may be due to the selective loss of 
CCR1:CXCL4 signalling in macrophages within plaques that normally would lead to lower modified LDL uptake. 
Although CXCL4 deletion has previously been shown to be atheroprotective on the Apolipoprotein E null back-
ground11, such a broad stroke removes a number of potentially pro-atherosclerotic CXCL4 activities outside of 
CCR1 signalling, such as promoting oxidised LDL binding to the vasculature and inhibiting oxLDL endocytosis 
by the LDL receptor40 in addition to T cell recruitment via CXCR3-B17. We would suggest that when contemplat-
ing targeting CXCL4 in the treatment of atherosclerosis, alongside the pro-atherosclerotic activities of CXCL4, 
the anti-atherogenic properties of M4 macrophages must also be considered41.
Assuming the in vitro data described here extrapolates to the clinical setting, then it would strongly argue 
against targeting CCR1 in atherosclerosis and may point to unforeseen side effects following the long-term use 
of such molecules for the treatment of other inflammatory disorders. Of note, the small molecule CCR1 antag-
onist CCX354 has shown efficacy in a phase II clinical trial for the treatment of rheumatoid arthritis and larger, 
longer-term clinical trials have been planned42. Since accelerated atherosclerosis and increased mortality is often 
observed in arthritic patients (reviewed in43), blockade of CCR1 may be detrimental. Further experimentation to 
test such a hypothesis in vivo is highly desirable.
Methods
Materials. Recombinant chemokines were from PeproTech EC Ltd (London, UK). The CCR1 antagonists 
UCB 35625 and BX-471 were from BioTechne Ltd. (Abingdon, UK) and have previously been described28,44. 
Bordetella pertussis toxin and the mouse isotype-matched control IgG1 (MOPC 21 clone) were from Sigma-
Aldrich (Poole, UK), as were heparinase and chondroitinase ABC. Radioiodinated CXCL10 and CCL3 were from 
Perkin Elmer Life Sciences (Boston, MA). The anti-human CCR1 and CXCR3 mAbs (MAB145 and MAB160, 
respectively) were from BioTechne Ltd. The anti-HA mAb was from Covance Biosciences (Crawley, UK). The 
secondary anti-mouse-FITC conjugated antibody was from DAKO UK Ltd, (Cambridge, UK). All other reagents, 
unless noted, were from Life Technologies (Paisley, UK).
Cell Preparation and Maintenance. Blood was taken from healthy normal subjects with written informed 
consent. The protocol was approved by the Brompton, Harefield and NHLI ethics committee. All experiments 
Figure 11. CXCL4 undergoes cis presentation to CCR1 to facilitate monocyte migration. The question mark 
denotes an as yet unidentified glycosaminoglycan decorated with chondroitin sulphate.
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were carried out in accordance with the approved guidelines. PBMCs were isolated as previously described28. 
THP-1 and L1.2 cells were maintained as previously described44. Where indicated, cells were treated over-
night with 100 ng/ml pertussis toxin (Sigma-Aldrich) to inhibit Gαi signaling. For studies of monocyte chem-
otaxis, monocytes were separated from whole blood using a Rosette-Sep monocyte purification kit (StemCell 
Technologies, Grenoble, France) according to the manufacturer’s instructions. Transient transfection of L1.2 cells 
with HA-tagged chemokine receptor constructs was by electroporation as previously described44.
Flow cytometric analysis of chemokine receptor expression. Staining of HA-tagged CCR1, CCR2 
and CCR3 transfectants was by the use of an anti-HA monoclonal as previously described44. Detection of CCR1 
with MAB145 was as described previously45. Flow cytometry analysis was carried out using a LSR Fortessa or 
FACS Calibur (BD Bioscience, Oxford, UK); gating excluded cell debris and cell doublets from analysis.
Cell Migration Assays. Modified Boyden Chamber assays were carried out as previously described44 using 
5 μm pore chambers (Neuroprobe Inc, Gaithersburg, MD). In experiments employing pertussis toxin, cells were 
pretreated with 100 ng/ml for 18 hours at 37 °C. Similarly, in experiments employing the glycosidases hepari-
nase and chondroitinase ABC, cells were incubated with agitation with one unit/ml of enzyme for 30 minutes 
at 37 °C as previously described25, before being washed extensively in phosphate buffered saline. In experiments 
employing the CXCR3 or CCR1 antagonist, chemokine dilutions were made in a solution containing a fixed con-
centration of the competitor. In experiments to assess the contribution of chemokinesis, the same concentration 
of chemokine placed in the lower well of the chemotaxis chamber was present in the assay buffer, eliminating the 
chemoattractant gradient.
For real time analysis of migrating THP-1 cells and freshly isolated monocytes, a 12-channel TAXIScan was 
employed27 and used according to the manufacturer’s protocol (Effector Cell Institute, Tokyo. Japan). Where 
indicated, cells were pretreated with a fixed concentration of antagonist for 30 minutes at 37 °C prior to carrying 
out the assay. One μl of a suspension containing 500,000 cells/ml was loaded into each chamber and following 
alignment of the cells at one end of the terrace, 1 μl of chemokine (1 μM CCL2 or 20 μM CXCL4) was added 
to the other end of the terrace (260 μm away) and cells were allowed to migrate along the ensuing chemokine 
gradient for 2 hr whilst maintained at 37 °C (Supplementary Figure 2). Sequential image data were captured at 
every minute as individual jpegs. To calculate the mean track length, data were subsequently processed with 
ImageJ (National Institutes of Health), equipped with the manual tracking tool plugin (Fabrice Cordelieres, 
Institut Curie, Orsay (France) and chemotaxis tool plugin (Ibidi, Martinsried, Germany). Individual experiments 
consisted of duplicate conditions and data illustrated are collated from several experiments as highlighted in the 
figure legend. The numbers of cells tracked under each condition are shown in the figure. For each individual cell, 
the mean track length was calculated by the chemotaxis tool plugin as described previously46. The accumulated 
distance parameter (Fig. 10) refers to the total distances traveled by all cells for a particular condition in an indi-
vidual experiment.
Cell migration was also manually tracked using TAXIScan Analysis software in order to generate plots of 
Velocity versus Directionality. This is an accepted methodology for accurately distinguishing chemotaxis from 
chemokinesis with the TAXIScan system27. The direction of cell migration is expressed as the angle (rad) towards 
the concentration gradient, namely π/2 indicates that the cell is migrating toward the concentration gradient, 
whereas −π/2 indicates that the cell is migrating against the concentration gradient. Velocity-Directionality-Box 
(VD-B) plots were subsequently generated47 in which the vertical axis shows the median value of velocity and the 
horizontal axis shows the median value of the directionality. For THP-1 cells, tracking was undertaken during 
the initial 30 minutes of migration, whereas for slower moving monocytes, tracking was carried out for the first 
60 minutes of migration.
Intracellular Calcium Measurements. These were performed as previously described19 using cells that 
were loaded with the fluorescent dye FURA-2 AM (Life Technologies). Real time data were recovered using a 
fluorimeter (LS-50B, Perkin-Elmer, Beaconsfield, UK). Data are expressed as the relative ratio of fluorescence 
emitted at 510 nm after sequential stimulation at 340 and 380 nm.
CCR1 Endocytosis Assays. THP-1 cells were cultured with 80 nM calcitriol (Sigma-Aldrich) for 48 hr to 
enhance CCR1 expression48. Similarly, CCR1-L1.2 transfectants were cultured overnight with 10 mM sodium 
Butyrate to enhance CCR1 expression44. Human monocytes were used within an hour of purification. Cells were 
resuspended at 500,000 cells/ml in RPMI, 0.1 % BSA and kept on ice. Aliquots of these cells (50 μl) were incu-
bated with either an identical volume of buffer alone or buffer containing CCL3 or CXCL4, giving a final con-
centration of 50 nM CCL3 or 1 μM CXCL4. Samples were either left at 4 °C for 30 minutes or incubated at 37 °C 
for 30 minutes after which they were stained for CCR1 expression by flow cytometry as described above. Data is 
presented as the percentage of CCR1 staining observed in the buffer treated samples that were incubated on ice.
Statistical Analysis. Statistical analyses were carried out using Prism 6 (GraphPad Software, La Jolla, CA). 
Unless otherwise stated, data reflect the mean values ± SEM from the number of experiments shown in parenthe-
sis. Unless otherwise stated, statistics refer to repeated measures ANOVA with Bonferroni’s post-test. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. NS denotes not significant.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
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